BCD-085: Phase II started

Biocad began a double-blind, placebo-controlled, international Phase II trial to evaluate 40, 80 and 120 mg subcutaneous BCD-085 at weeks 0, 1, 2, 4, 6, 8 and 10 in about 120 patients. ...